School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.
Macular Degeneration Foundation Australia, Sydney, Australia.
Clin Exp Optom. 2021 Jul;104(5):561-566. doi: 10.1080/08164622.2021.1878866. Epub 2021 Feb 27.
Dry eye disease is one of the most common, chief-complaints presenting in clinical practice, with a prevalence of up to 50%. Evaporative dry eye, as a result of meibomian gland dysfunction, is thought to be the biggest component factor. Treatments for meibomian gland dysfunction aim to restore tear film homoeostasis and include warm compress therapy, eyelid hygiene, in-office meibomian gland expression and lipid-containing, artificial tears. A recent introduction to the in-office treatments available for meibomian gland dysfunction has been low-level light therapy, also known as photobiomodulation. The technique involves applying red, or near infra-red, radiation using low-power light sources and is suggested to promote tissue repair, decrease inflammation, and relieve pain. This work aims to review the available literature on the efficacy and safety of photobiomodulation in meibomian gland dysfunction and dry eye disease, as well as what is currently known about its mechanism of action.
干眼症是临床实践中最常见的主诉之一，患病率高达 50%。蒸发性干眼症，由于睑板腺功能障碍，被认为是最大的组成因素。睑板腺功能障碍的治疗旨在恢复泪膜的动态平衡，包括热敷治疗、眼睑卫生、睑板腺内按摩和含脂、人工泪液。最近引入的睑板腺功能障碍的治疗方法是低水平光疗，也称为光生物调节。该技术包括使用低功率光源施加红色或近红外辐射，并被认为可促进组织修复、减少炎症和缓解疼痛。这项工作旨在回顾光生物调节在睑板腺功能障碍和干眼症中的疗效和安全性的现有文献，以及目前对其作用机制的了解。
